Sensei Biotherapeutics (NASDAQ:FTH) Hits New 1-Year High – Should You Buy?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $41.16 and last traded at $40.9250, with a volume of 274991 shares traded. The stock had previously closed at $40.05.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on FTH. Raymond James Financial assumed coverage on Sensei Biotherapeutics in a research report on Friday, July 31st. They issued an “outperform” rating and a $56.00 price target on the stock. Citigroup initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $55.00 target price on the stock. Loop Capital set a $50.00 target price on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics in a research report on Friday, August 21st. They issued a “buy” rating and a $56.00 price target on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Sensei Biotherapeutics Price Performance

The firm has a market capitalization of $933.34 million, a PE ratio of -0.25 and a beta of -0.28. The business has a 50-day moving average price of $30.73.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping the consensus estimate of ($5.04) by $2.20. Research analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current year.

Insider Activity

In other news, CEO Anand Kiran Parikh bought 2,806 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the acquisition, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Brian C. Stephenson bought 9,391 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were acquired at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the transaction, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. This represents a 53.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 49,494 shares of company stock worth $1,188,822 over the last three months. Insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Several large investors have recently modified their holdings of FTH. Vivo Capital LLC bought a new position in Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Alyeska Investment Group L.P. bought a new stake in shares of Sensei Biotherapeutics in the 2nd quarter valued at about $3,610,000. Stempoint Capital LP bought a new position in Sensei Biotherapeutics during the 1st quarter worth approximately $4,188,000. Bank of America Corp DE grew its holdings in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the period. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.